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Immunosuppressive pretransplantation conditioning is essential for donor cell engraftment in allogeneic
bone marrow transplantation (BMT). The role of residual postconditioning recipient immunity in determining
engraftment is poorly understood. We examined the role of recipient perforin in the kinetics of donor cell
engraftment. MHC-mismatched BMT mouse models demonstrated that both the rate and proportion of donor
lymphoid cell engraftment and expansion of effector memory donor T cells in both spleen and BM
were signiﬁcantly increased within 5 to 7 days post-BMT in perforin-deﬁcient (pfn/) recipients, compared
with wild-type. In wild-type recipients, depletion of natural killer (NK) cells before BMT enhanced donor
lymphoid cell engraftment to that seen in pfn/ recipients. This demonstrated that a perforin-dependent,
NK-mediated, host-versus-graft (HVG) effect limits the rate of donor engraftment and T cell activation.
Radiation-resistant natural killer T (NKT) cells survived in the BM of lethally irradiated mice and may drive
NK cell activation, resulting in the HVG effect. Furthermore, reduced pretransplant irradiation doses in pfn/
recipients permitted long-term donor lymphoid cell engraftment. These ﬁndings suggest that suppression of
perforin activity or selective depletion of recipient NK cells before BMT could be used to improve donor stem
cell engraftment, in turn allowing for the reduction of pretransplant conditioning.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell (HSC) transplantation is an
effective therapy for a number of blood cancers, including
leukemia and lymphoma, by reconstituting a patient’s
immune system with donor immune cells that mediate a
graft-versus-tumor effect. Clinical outcome is dependent on
rapid donor cell engraftment, immune reconstitution, and
potent control of tumor without the development of graft-edgments on page 248.
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ty for Blood and Marrow Transplantation.versus-host disease (GVHD). Pretransplant immunosup-
pressive conditioning is required for complete donor
engraftment of the bone marrow (BM) and to prevent graft
rejection. However, preconditioning using chemotherapy
with or without total body irradiation (TBI) results in sig-
niﬁcant morbidity and contributes to the onset of acute
GVHD.
Mouse models of BM transplantation (BMT) and GVHD
have contributed greatly to our understanding of the early
immune events post-transplant leading to the activation of
donor cells, mimicking human disease (reviewed in [1]).
Damage of the intestinal mucosa after pretransplant con-
ditioning permits the release of pathogen-/danger-associ-
ated molecular patterns that triggers activation of residual
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rapid secretion of pro-inﬂammatory cytokines [2,3]. The
initial priming phase of allogeneic CD4þ donor T cells
largely occurs via the recognition of minor hematopoietic
antigens presented on MHC class IIepositive non-
hematopoietic recipient APC in the gut [4,5] and by he-
matopoietic APC in the lymphoid tissue for CD8þ T cells
[6,7]. Hyperactivation of donor lymphoid cells leads to a
“cytokine storm” characterized by elevated IL-6, IFN-g,
tumor necrosis factor-a, IL-21, and IL-17 levels [8]. This
provides a pro-inﬂammatory milieu that subsequently
drives the differentiation and expansion of donor regula-
tory T cells, natural killer (NK) cells, and allogeneic T cells,
contributing to acute GVHD.
The cytotoxic granule proteins, perforin and granzymes,
have well-characterized donor allogeneic NK and T
cellemediated graft-versus-tumor and GVHD effects [9-11].
In addition to their ability to induce apoptosis of allogeneic
target cells, these cytotoxic proteins have increasingly
diverse functions, including restricting antigen presenta-
tion and T cell activation during virus infection [12], exac-
erbating sepsis [13], and, counterintuitively, impeding
antitumor responses by directly killing CD8þ T cells [14].
Although donor perforin-dependent and -independent,
context-dependent effects on GVHD have been previously
described [9,10,15-22], the role of perforin in recipient mice
remains uncertain. Bennett et al. [23] identiﬁed that
recipient perforin modulates donor engraftment in an MHC
class Iedeﬁcient mouse model, consistent with NK medi-
ated rejection of donor stem cells with “missing-self.” In
contrast, perforin was dispensable in preprimed HLA-
matched, CD8þ T celledependent mouse models of short-
term myeloid engraftment [24,25]. Furthermore, others
have described that NK depletion in recipient mice, using
anti-Asialo GM1 treatment, increased the kinetics of he-
matopoietic cell reconstitution and the rate of donor cell
engraftment in mouse BMT models [26,27]. Recently, the
generation of the Mcl-1 knockout mouse [28] conﬁrmed
the importance of recipient NK cells in regulating BM
engraftment. Additionally, recipient NKT natural killer T
(NKT) cells can regulate BM engraftment and GVHD by
activating donor regulatory T cells via an IL-4edependent,
NK celledependent mechanism [29,30]. Therefore, it is
becoming increasingly apparent that cytotoxic proteins,
such as perforin, and the cells that express them play an
important role in post-transplant immune function.
We hypothesized that perforin expression in BMT
recipients is important for inhibiting donor lymphocyte
engraftment and allogeneic T cell activation. In 2
MHC-mismatched mouse models of BMT, we found that
donor lymphoid cell engraftment, expansion of effector
memory allogeneic T cells, and release of pro-inﬂammatory
cytokines were accelerated in perforin-deﬁcient recipients
compared with wild-type (WT) recipients. Enhanced donor
cell engraftment in the absence of perforin in recipient
immune cells was attributed to a decreased host-versus-
graft effect via radiation-resistant, NK cellemediated
killing of allogeneic donor cells. Long-term donor lymphoid
cell engraftment in perforin-deﬁcient recipients persisted
when the pretransplant TBI dose was reduced. Therefore,
inhibition of recipient perforin function at the time of BMT
in combination with reduced-intensity conditioning
may improve donor cell engraftment and minimize
conditioning-related side effects.METHODS
Mice and BMT Models
All animal work was conducted in an speciﬁc-pathogen-free (SPF) fa-
cility at the Peter MacCallum Cancer Centre, under institutional animal
ethics committee approved protocols. Female 6- to 14-week-old BALB/c WT
and BALB/c.perforin knockout (KO) mice (bred and housed at Peter Mac-
Callum Cancer Centre Animal Facility) (H-2Kd) and C57BL/6 WT and C57BL/
6.perforin KO mice (H-2Kb) were used as BMT recipients. MHC-disparate
models of BMT were established, transplanting BALB/c donor BM into
C57BL/6 recipients (H-2Kdab) or C57BL/6 BM into BALB/c recipients (H-
2Kbad).
On day 0, recipient mice were administered a split dose of lethal radi-
ation using a cesium source (2  6 gray for C57BL/6 and 2  5.5 gray for
BALB/c) and injected i.v. with 5e6 T celledepleted BM (TCD-BM) cells from
MHC-mismatched or syngeneic donors. On day 2, recipient mice were
injected i.v. with 2e5 C57BL/6 or 1e6 BALB/c puriﬁed splenic T cells at a 2:1
CD4þ/CD8þ T cell ratio. Mice were monitored daily and killed at selected
time points post-transplant (typically days 5 to 7 for short-term engraft-
ment or day 20 for long-term engraftment) to examine donor lymphoid cell
engraftment.
Serum was collected for cytokine analysis and the spleen, gut, and BM
harvested for phenotypic and histological analysis. NK cells were depleted
by injecting 100 mL rabbit anti-Asialo GM1 antibody (Wako, Chuo-Ku, Osaka,
Japan) i.p. into mice on days 1 and 0. Control mice were injected with PBS.
MACS Bead Puriﬁcation
T cells were depleted from donor BM using a magnetic activated cell
sorting (MACS) mouse CD3e microbead kit, following manufacturer’s in-
structions (Miltenyi Biotec, Bergisch Gladbach, Germany). Splenic T cells
were puriﬁed using MACS CD4þ T cellenegative selection or CD8þ T celle-
negative selection beads and mixed at a 2:1 ratio before injecting into mice.
Flow Cytometry
Lymphocytes isolated from BM and spleen were washed and resus-
pended in FACS buffer (PBS þ 2% FCS). Nonspeciﬁc binding was blocked
using the 2.4G2 hybridoma (ATCC HB-197, USA) before staining with anti-
mouse mAbs for 30 minutes on ice and thenwashing and ﬁxing the cells in
2% paraformaldehyde. The antibody panel included H-2Kb-PE, H-2Kd-FITC,
CD8a-PeCy7, CD44-FITC, CD62L-APC, CD19-PerCpCy5.5, NK1.1-PeCy7 (BD
Biosciences, San Jose, CA), CD3e-eFluor450, CD4-APC AF780 (eBioscience
San Diego, CA, Carlsbad, CA), and live/dead ﬁxable AmCyan (Invitrogen, Life
Technologies). Mouse CD1d-aGalCer (PBS44) tetramers were provided as a
kind gift from Dale Godfrey, University of Melbourne. Cells were acquired
on an LSRFortessa (BD Biosciences, San Jose, CA) and results analyzed using
FlowJo (TreeStar, Ashland, OR) software.
Cytokine Detection
Serum cytokine levels were measured using Luminex multiplex assays.
Serum was stored at 20C until tested by Luminex assay, as per the man-
ufacturer’s instructions (Merck Millipore, Darmstadt, Germany).
Statistical Analysis
Results from pooled experiments were analyzed using GraphPad Prism
software (La Jolla, CA), using the unpaired t-test. Mouse survival curves were
analyzed using the log-rank (Mantel-Cox) test. Signiﬁcant results were
plotted as P < .05, P < .01, P < .001, and P < .0001.
RESULTS
Absence of Recipient Perforin Contributes to Donor
Lymphoid Cell Engraftment
To investigate the role of recipient perforin in regulating
donor lymphoid cell engraftment, we used 2 MHC-
mismatched models, transplanting WT donor cells into WT
or pfn/ recipients. The percent of total body weight was
determined for spleens harvested on day 5 or 7 post-BMT in
C57BL/6 WT or pfn/ recipient mice (Figure 1A). At both
early time points, the spleen size was signiﬁcantly increased
in pfn/ recipients compared with theWTcounterparts (P<
.0001). Enlarged spleens were only observed in pfn/ re-
cipients after allogeneic BMT, as after syngeneic transplants
the spleen sizes were similar for both WT and pfn/ mice
(Supplementary Figure 1), indicating no underlying differ-
ence in spleen size solely because of perforin deﬁciency.
Figure 1. The absence of recipient perforin contributes to donor lymphoid cell engraftment. On day 0, C57BL/6 (WT) or C57BL/6.Pfn/ (KO) mice were lethally
irradiated (12 gray) and injected i.v. with 5e6 TCD-BM cells from BALB/c donors. On day 2, recipient mice were injected i.v. with 1e6 splenic BALB/c T cells. (A) On days
5 and 7, mice were killed and the spleenweight measured as a percentage of total body weight. (B) On day 7 after BMT, the splenocytes and BM cells of WT or KOmice
were stained for H2Kd (donor cells), by ﬂow cytometry, and engraftment determined as a percentage of donor lymphocytes. (C and D) On days 5 to 9 after BMT, serum
was collected from WT or KO mice and measured for IFN-g (C) or IL-6 (D) release, by Luminex assay. These data summarize 5 independent experiments using 5 mice
per group. P < .05 (*), P < .01 (**), P < .001 (***), P < .0001 (****).
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by ﬂow cytometry on spleen or BM cells at day 7 post-BMT,
using H-2Kd as a marker for BALB/c donor cell engraftment.
There was an enhanced rate of donor lymphoid cell
engraftment in pfn/ recipient mice in both the spleen and
BM cells (P< .0001, Figure 1B) and also of donormyeloid cells
(DNS). Similar results were found for BALB/c-background
recipient mice, using C57BL/6 donor cells (Supplementary
Figure 2), conﬁrming reproducibility in the reverse mis-
matched model, and were not used for the remainder of this
study.
Coinciding with accelerated donor lymphoid cell
engraftment, pfn/ recipient mice often succumbed to acuteFigure 2. Differentiation of effector donor T cells occurs more rapidly in the absence o
lethally irradiated (12 gray) and injected i.v. with 5e6 TCD-BM cells from BALB/c donor
7, mice were killed and splenocytes stained with CD3, CD4, CD8, CD62L, and CD44 m
cytometry. (A) A representative FACS analysis contour plot indicating central memory
C) The percentage of central memory and effector memory CD4þ (B) and CD8þ (C) T ce
data summarize 3 independent experiments using 5 mice per group. P < .05 (*), P <GVHD and were culled around days 9 and 10 post-BMT
because of losing more than 20% starting body weight and
symptoms of GVHD (Supplementary Figure 3). Another
hallmark of early-onset GVHD is elevated pro-inﬂammatory
cytokine release into the serum. Between 5 and 9 days
post-BMT, IL-6 and IFN-g were elevated in pfn/ mice,
compared with WT recipients (P < .0001 at day 7,
Figure 1C,D).
Differentiation of Effector Donor T Cells Occurs More
Rapidly in the Absence of Recipient Perforin
Given the elevated levels of pro-inﬂammatory cytokines
in the serum of pfn/ recipients, we next investigated thef recipient perforin. On day 0, C57BL/6 (WT) or C57BL/6.Pfn/ (KO) mice were
s. On day 2, these mice were injected i.v. with 1e6 splenic BALB/c T cells. On day
Abs and ﬁxable Live/Dead. Viable donor CD3þ T cells were analyzed by ﬂow
(CM; CD62LþCD44þ), and effector memory (EM; CD62LCD44þ) T cells. (B and
lls were compared between WT and KO BMT recipients 7 days post-BMT. These
.01 (**), P < .001 (***), P < .0001 (****).
Figure 3. Recipient NK cells mediate donor lymphoid cell rejection in a perforin-dependent manner. On days1 and 0, C57BL/6 (WT) or C57BL/6.Pfn/ (KO) mice were
injected i.p. with 100 mL anti-Asialo GM1 (GM1) or PBS. On day 0, WT and KO mice were lethally irradiated (12 gray) and injected i.v. with 5e6 TCD-BM cells from BALB/c
donors. On day 2, these mice were injected i.v. with 1e6 splenic BALB/c T cells. On day 7 after BMT, the splenocytes (A) and BM cells (B) of WT or KO mice were stained for
H2Kd (donor cells), by ﬂow cytometry, and engraftment determined as a percentage of donor lymphocytes. (C and D) On day 7 after BMT, serumwas collected fromWT
or KO mice and measured for IFN-g (C) or IL-6 (D) release, by Luminex assay. These data summarize 2 independent experiments using 5 mice per group. P < .05 (*), P <
.01 (**), P < .001 (***), P < .0001 (****).
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differentiationwas assessed 7 days post-BMT (Figure 2A) and
correlated with the elevated IFN-g levels observed in
Figure 1. We found a signiﬁcant increase of donor-derived
effector memory (CD44þCD62L) CD4þ and CD8þ T cells in
pfn/ recipients (P < .0001, Figure 2B,C). In contrast, 60% to
70% of donor T cells in WT recipients retained a central
memory (CD44þCD62Lþ) phenotype.Recipient NK Cells Mediate Donor Lymphoid Cell Rejection
in a Perforin-Dependent Manner
Because perforin function in BMT recipient mice was vital
for controlling early allogeneic T cell engraftment, we wanted
to determine if NK cells were a key effector cell in regulating
this process. We depleted NK cells in WT recipients using the
anti-Asialo GM1 (GM1) antibody, before BMT, to see if this
accelerated donor lymphoid cell engraftment. The relative
spleen size in WT mice pretreated with GM1 antibody was
similar to pfn/ recipients who were treated with GM1 or
PBS (DNS). Donor cell engraftment in both the spleen and BM
was accelerated in WT mice pretreated with GM1, restoring
engraftment levels to that observed in pfn/ recipients (P <
.0001, Figure 3A,B). Furthermore, NK depletion in WT mice
resulted in signiﬁcantly increased IFN-g and IL-6 secretion in
the serum 7 days post-BMT to levels observed in pfn/ mice
(Figure 3C,D). However, NK depletion in pfn/ mice did
not further enhance donor lymphoid cell engraftment orpro-inﬂammatory cytokine secretion, because donor NK cells
are themain drivers of the host-versus-graft effect. These data
demonstrate the importance of recipient NK cells in control-
ling the rate of donor cell engraftment post-BMT and the role
of recipient perforin function in mediating this effect.Anti-Asialo GM1 Treatment Depletes NK1.1þ Tetramer
Cells in the BM but not the NKT Tetramerþ Cells
Based on our data, it was apparent that a radio-resistant
population of perforin-expressing effector cells controlled
donor lymphoid cell engraftment. To clarify which radio-
resistant lymphoid cell subsets may be affected by the le-
thal radiation dose and GM1 treatment, we examined the BM
of mice 2 days after irradiation. We compared untreated,
irradiated only, and irradiatedþGM1 treated WT mice and
analyzed the BM lymphoid cells by ﬂow cytometry. The
percentage of CD3þ T cells in the viable lymphocyte gate was
signiﬁcantly increased 2 days after irradiation (P < .0001)
and did not change with GM1 treatment (Figure 4A). Use of
GM1 in WT mice selectively depleted NK1.1þCD3 cells in
the BM as expected but as previously reported did not affect
the frequency of NKT cells [31,32]. NK1.1þCD3 cells also
increased signiﬁcantly after irradiation but were effectively
depleted after GM1 treatment on days 1 and 0 (P < .0001,
Figure 4B). Furthermore, the percentage of NKT
(NK1.1þCD3þ) cells increased in the BM post-irradiation (P <
.0001) but was unaffected by NK depletion (Figure 4C). We
Figure 4. Anti-AsialoGM1treatmentdepletesNK1.1þtetramer cells intheBMbutnot theNK1.1þtetramerþ cells.Ondays1and0,C57BL/6(WT)micewere injectedi.p.with
anti-AsialoGM1(GM1)orPBS.Onday0,WTmicewere lethally irradiated(12gray).Onday2 theBMcellswere stainedwithCD3andNK1.1mAbs,CD1d-aGalCer tetramer, and
ﬁxable Live/Deadandanalyzedbyﬂowcytometry. Thepercentage ofCD3þ Tcells (A), NK1.1þCD3-NK cells (B), andNK1.1þCD3þNKTcells (C) inviable BMcellswere compared
between untreated, irradiated, and irradiatedþ anti-Asialo GM1 treatedmice. The percentage of NK1.1þtetramer (D) and NK1.1þtetramerþ (E) cells in viable BM cells were
compared between the same cohorts. These data summarize 2 independent experiments using 5 mice per group. P < .05 (*), P < .01 (**), P < .001 (***), P < .0001 (****).
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(PBS44) tetramer (Figure 4D,E), which conﬁrmed the NK1.1/
CD3 phenotype observations in Figure 4B,C. Perforin deﬁ-
ciency did not alter the radiation phenotype found in WT
mice (DNS); therefore, it is unlikely pfn/ cells had
increased sensitivity to radiation-induced cell death.
Reduced TBI in Perforin-Deﬁcient Mice Permits Rapid
Donor Lymphoid Cell Engraftment
Because accelerated donor cell engraftment is associated
with increased levels of pro-inﬂammatory cytokines and the
onset of acute GVHD, we next wanted to examine the effect
of reducing the preconditioning regimen before BMT. We
reduced the radiation dose administered to recipient mice to
determine if donor cell engraftment could be maintained in
the absence of perforin, without illness caused by the cyto-
kine storm. WT or pfn/ recipient mice received 12 gray
(predetermined lethal dose) or 10, 8, or 6 gray on day 0 of the
BMT, and then donor cell engraftment was measured after 7
days. Spleen size (DNS) and donor cell engraftment in the
spleen and BM decreased in the pfn/ recipients as the ra-
diation dose was reduced (Figure 5A,B). At day 7, the level of
donor cell engraftment in pfn/ mice administered only 6
gray was similar to that observed in WT mice that received
12 gray. TheseWTmice were fully engrafted by 20 days post-
BMT (Figure 5C,D). We hypothesized that pfn/ recipient
mice administered a reduced dose of radiation could also
maintain long-term engraftment, without succumbing to
cytokine-mediated toxicity.Similarly to the short-term engraftment experiments
described in Figure 5A,B, pfn/ BMT recipients given 9 gray
pretransplant consistently fully engrafted with donor cells
after 20 days (Figure 5C,D). In addition, 4/7 pfn/ mice that
received 7.5 gray also engrafted after 20 days, although all
mice receiving 6 gray rejected the donor graft. However,
although the reduced radiation dose in pfn/ mice was
associated with improved donor lymphoid cell engraftment,
the overall survival of thesemicewas compromised (P< .001,
Figure 5E), whereby most mice receiving 9 gray had to be
killed by day 20 because of symptoms of acute GVHD.
Additionally, most pfn/ mice pretreated with 9 gray lost
more than 20% body weight within the ﬁrst 10 days post-
BMT, compared with WT mice receiving 12 gray, which
fully recovered from radiation-induced weight loss and sur-
vived the monitoring period without developing GVHD
(Figure 5F).
DISCUSSION
Using MHC-mismatched mouse models, we identiﬁed a
critical role for perforin-expressing NK cells in regulating
both the rate and activation status of donor lymphocyte
engraftment after allogeneic transplantation. In perforin-
deﬁcient recipients, the absence of host-mediated control
of donor engraftment resulted in rapid donor lymphoid and
myeloid cell engraftment, expansion of effector memory T
cells, and the production of pro-inﬂammatory cytokines,
leading to a rapid onset of fatal GVHD. In the absence of the
perforin-mediated regulation of engraftment, pretransplant
Figure 5. Reduced TBI in perforin-deﬁcient mice permits rapid donor lymphoid cell engraftment. On day 0, C57BL/6 (WT) or C57BL/6.Pfn/ (KO) mice were irradiated
with variable doses (12-6 gray) and injected i.v. with 5e6 TCD-BM cells from BALB/c donors. On day 2, recipient mice were injected i.v. with 1e6 splenic BALB/c T cells. On
day 7 after BMT, the splenocytes (A) and BM cells (B) of WT or KO mice were stained for H2Kd (donor cells), by ﬂow cytometry, and engraftment determined as a
percentage of donor lymphocytes. On day 20 after BMT, the splenocytes (C) and BM cells (D) of WT or KO mice were stained for H2Kd (donor cells), by ﬂow cytometry,
and engraftment determined as a percentage of donor lymphocytes. (E) Survival of WT mice administered 12 gray (open circles), and KO mice administered 9 gray
(closed circles), 7.5 gray (triangles), and 6 gray (squares) after BMT described above. (F) The percentage body weight of WTmice (12 gray [gray lines]), compared with KO
mice (9 gray [black lines]) after BMT. These data summarize 2 independent experiments using 6 mice per group. P < .05 (*), P < .01 (**), P < .001 (***), P < .0001 (****).
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simultaneously maintaining engraftment and reducing rates
of GVHD. Subsequent depletion studies suggested that radio-
resistant recipient NK cells were responsible for perforin-
dependent regulation of donor T cell engraftment.
Although recipient perforin has previously been shown to
modulate myeloid engraftment from mouse bone marrow
[23] and when given by adoptive transfer NK cells can
ameliorate the onset of GVHD [33], the role of perforin-
expressing endogenous recipient NK and NKT cells in modu-
lating donor T cell engraftment has not been described. The
rapid expansion of effector memory donor T lymphocytes in
pfn/ recipients is a novel observation, possibly arising from
more rapid proliferation or selective survival of these donorcells. These cells contribute to the pro-inﬂammatory cascade
responsible for early-onset GVHD. Critically, our ﬁndings
showed that absence of perforin resulted in the increased
production of inﬂammatory cytokines, in particular IL-6,
which has been identiﬁed as a primary driver of both mouse
model and clinical GVHD [34]. Consequently, novel immuno-
therapies that target IL-6 production for the prevention and
treatment of GVHD have been developed and are currently
being evaluated in clinical trials [35].
Recently, granzyme B expression by recipient lymphoid
cells has also been implicated in the regulation of donor HSC
engraftment, via both intrinsic and extrinsic mechanisms
[36]. Granzyme Bedeﬁcient recipient mice demonstrated
superior engraftment of WT HSC, and, correspondingly,
J.E. Davis et al. / Biol Blood Marrow Transplant 21 (2015) 242e249248granzyme Bedeﬁcient HSC engrafted more rapidly in WT
recipients. Intriguingly, the absence of granzyme B contrib-
uted to improved HSC function, including increased prolif-
eration and mitochondrial activity, possibly protecting HSC
from postconditioning stress. It will be interesting to
examine if the absence of perforin contributes to a similar
phenotype, as we observed the rapid expansion and differ-
entiation of effector memory donor T cells in pfn/ mice.
The ability of endogenous lymphocyte populations to
modulate donor lymphoid engraftment relies on their
persistence after completion of conditioning. TBI has previ-
ously been shown to promote the selective survival of
CD4þBcl2þ IL-4 expressing NKTcells, which increase over 10-
foldwithin 24 hours [37].We found that alongwith increased
BM NKT cells, CD3þ T cells and NK cells also increased in fre-
quency 2 days after irradiation. Recipient invariant NKT cells
are known to play a crucial role in regulating early events
post-BMT, primarily through the secretion of Th1 and Th2
cytokines, driving the expansion of donor regulatory T cells
and the activation of NK cells [32,37,38]. BMT recipient mice
lacking NKT cells or IL-4 develop GVHD more rapidly than
their WT counterparts, presumably through a diminished
host-versus-graft response [29,37], although the rate of donor
cell engraftment was not examined in these studies.
The challenge in clinical HSC transplantation is to pro-
mote reliable donor engraftment and full immunological
reconstitution while minimizing pretransplant conditioning
and associated toxicity. Based on our study ﬁndings, pres-
ervation of endogenous NK and NKTcell populations through
reduction in the intensity of pretransplant conditioning is
likely to result in enhanced control of lymphocyte engraft-
ment, reduced T cell activation, and lower cytokine produc-
tion. We demonstrated that in the absence of functional
perforin, we could signiﬁcantly reduce pretransplant TBI
doses and still maintain long-term donor lymphoid cell
engraftment. However, despite this, pfn/ recipients treated
with reduced TBI doses continued to show decreased sur-
vival rates, compared with WT mice treated with 12 gray.
Further work is required to understand the combined effects
of lowering both the conditioning and the T cell infusion dose
into perforin-deﬁcient recipients.
A ﬁne balance exists between maintaining sufﬁcient
control over donor T cell engraftment and preventing graft
rejection. Conversely, the potential for future novel inhibitors
of perforin activity [39] in conjunction with reduced-
intensity conditioning may allow the combined advantage
of reduced transplant toxicity while maintaining donor
engraftment and promoting the graft-versus-tumor effect.
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